Master of Musical Chairs
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
more good news coming $OMHE will be over .10+ soon
I like you - have a great Saturday this is my 1 post allowed per day on this board $OWCP
big league $omhe
We shall see $OMHE
I'm going to say it now he's as good as it gets $OMHE to da MOON
I am considering it a rumor and treating it as such.. I have already loaded my position here and will be holding for HIGH SILVER potential PAPER here if you catch my drift it would make sense for all parties if $OMHE got into the cultivation process and with it being for medical purposes they will need GRO3 technology to ensure quality of the grow.. $OMHE could end up really being a fairytale story stock in 2018 #thousands2millions
WHOA this is huge news for $OMHE and $AMFE if true!!!!
Rocket this is the first I have heard of this! As you know I am an AMFE'r can you please elaborate? $OMHE and $AMFE ????
Do we have a list of stocks that will be included in this ETF? I know #$OWCP was mentioned as a stock in previous planned ETFs not sure if this one included, I am only allowed ONE POST PER DAY HERE so this is IT... have a great weekend HODL strong and propser
5million share volume day is coming soon and that will take us over .03 $OMHE going to be the TALK OF THE TOWN here shortly once details come out from the company next couple weekss
Going to be an epic chase once they announce details $OMHE #THOUSANDS2MILLIONS
great morning so far only going to get better churn and burn higher lows and higher highs all the way to HIGH HO SILVER!!!!!!!!!!!!!! .05 TO .10 TO .25+ $OMHE #THOUSANDS2MILLIONS
I am glad I was able to sell some shares in the mid night clay trader after hours chat room I was able to diversify a bit while I slept now I will buy back in on the clay dip he gives to all his paid members
$OMHE as the details come to light this will rise like the Phoenix bio tech takes time, Andrey was silent for a year but did everything recently to stay in good standings with pink sheets... WATCH OUT ABOVE!!!!!!!!! DOLLAR LAND COMETH
setting up for a sling shot soldier gotta think its coming on the next Press Release from the company ... gonna see a lot of buying on the rumor $OMHE
hey brother good 2 see you as well, $OWCP moved me out of Chicago and into the burbs bought a new house about 40min northwest of Ohare gonna be another rocket ship ride to dollar land I am thinking $5-8 this trip and a base around $3
PUMA will chase this into the .02s $OMHE #thousands2millions
LONELY BULL SAYS IT ALL lmfaooooooooooooooooooooooo $OWCP winners reap losers weep
On October 31, 2017, OWC Pharmaceutical Research Corp. (OTCQB: OWCP), hereinafter, the “Registrant”), appointed Ms. Hannah Feuer to serve as a member of the Board of Directors of the Registrant and Chairman of the Registrant’s Audit Committee.
WE NOW HAVE AN AUDIT COMMITTEE !! THIS IS SERIOUS WE ARE CROSS LISTING AND UPLISTING
Ms. Hannah Feuer, Age 62, Director and Chairman of the Audit Committee: Ms. Feuer is a CPA and Senior CFO with more than 20 years of experience in capital markets and management in financial institutions. During Ms. Feuer’s professional career, she has developed significant expertise working with boards of directors of both financial institutions and major companies and has extensive knowledge of public offerings and underwriting, as well as raising and managing private equity funds. In depth knowledge of operational management, including procurement and human resources. Since 2003, Ms. Feuer has served as group CFO of Poalim Capital Markets, one of Israel’s leading investment banks and a subsidiary of Bank Hapoalim, Israel’s largest financial group. She has also served as an independent director at Negev Ceramics Ltd from 2007 to 2012, prior to which Ms. Feuer served as a director at Bagir Ltd. from 2007 to 2009.
Got us some resistance to bust through alert city with a close over .40 $OWCP
$omhe
$OWCP notice we now have an audit division !!! UPLIST AND CROSS LISTING COMING HEAVY $OWCP
what a turn in the market sentiment on just a letter from Andrey the sleeping giant $OMHE about to turn thousands to millions #thousands2millions
yup that alone is worth billions and its not even on the radar yet.. $OWCP #thousands2millions
darn it we are gapping down today $OWCP darn it
$5+ then .. this shoots back over $2 very soon me thinks $OWCP
Travel, office space, office supplies etc.
I like that.. I use buy the silence sell the noise and in rare cases like $OWCP HODL ON FOE DEAR LIFE
SOLID AS A ROCK $OWCP MANAGABLE CASH BURN PLENTY OF ASSETS TO FUND US THROUGH THE YEAR AND THEN WE RAISE MORE CAPITAL AT WALL ST CONFERENCE TO FUND MYLEOMA TRIALS #THOUSANDS2MILLIONS
I bought a house with lottery tickets like $OMHE it's much easier to ride the wave then stopping a train butthurt OTC holders are the eptiomy of a sore loser plenty of money to be made average down or move on life is too short and trading OTC is too easy to whine
$OWCP https://friendsofsheba.org/tag/marijuana/ check out Sheba official website showing $OWCP as a friendly partner in arm
$OWCP and Sheba partnership ALONE IS WORTH 10S OF MILLIONS now add into trials, time, research, IP, patents you have a billion dollar pharma company GROSSLY UNDERVALUED HERE AT $50M MARKET TRADING GOING TO DOLLAR LAND BOYS AND GIRLS STRAP IN
Giddy up the dog days are over $OWCP
CSTI just parked at .047 its going to get super silly real fast here $OMHE amazing what a difference 24hrs can do for a ticker
Those are trades between market makers
I also received an email.. $OMHE
Dear xxx,
I would like to personally send you the letter to shareholders which went out this morning. Going forward we will be updating current and potential new shareholders continuously and hosting periodic phone-in conferences.
On a separate note, we would appreciate the intro to OWCx once we finalize the initiatives listed below within next several weeks. Thank you for your patience.
Andrey
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health’s annual revenues have grown to more than $4.6mln; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I’m working diligently to create a cycle of perpetual growth that over time I will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics— evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
About Omni Health Inc.
Omni Health, Inc., (OTC PINK: OMHE) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
Contact:
Andrey Soloviev
CEO
ceo@OmniHealth.md
exactly just pay us lmfaooooooooooooooooooooooooooooo
oh the possibilities $OMHE #thousands2millions
why you tink I am here besides for the fact I owe my buddy a bunch of fish tacos in return for the tip
lmfaooooooooooooooo $OMHE lets get it
$OMHE taking on the OPIOD crisis HEAD ON lets get it boys and girls #thousands2millions
to the untrained eye it seems old but a year in bio tech is like dog years lol